Study shows immune response to particular antigenic domain of CMV glycoprotein B
23 March 2018
Dr Ilona Baraniak, a Research Associate in the Griffiths-Reeves CMV team, recently published a paper in the Journal of Infectious Diseases.
The paper, 'Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine with MF59: Anti-AD2 Levels Correlate with Protection from Viremia', shows the immune response to a particular antigenic domain of CMV glycoprotein B as the explanation for the partial protection seen against CMV infection in transplant patients during a randomised controlled trial conducted at the Royal Free.
Dr Baraniak's article was selected to have an accompanying editorial.
- Read the paper via Journal of Infectious Diseases
- Read the editorial via Journal of Infectious Diseases
- Cytomegalovirus infection (Source: Wikimedia Commons)